Preclinical CRO, XenoTech, Joins Innovative, Full-Service CRO Alliance, next IND
Preclinical contract research organization (CRO), XenoTech, has announced its inclusion in next IND, an Integrated Service Network (ISN), designed to transform drug development in today´s fast-paced pharmaceutical landscape, where quality and time to market are of critical importance. next IND provides clients the convenience of a full-service provider with the specialized expertise and senior-level guidance from niche CROs.
Lenexa, KS (PRWEB) October 23, 2012
Preclinical contract research organization (CRO), XenoTech LLC, has joined next IND, an Integrated Service Network (ISN) designed to transform drug development in today´s fast-paced pharmaceutical landscape, where quality and time to market are of critical importance.
The pharmaceutical industry is experiencing increasing pressures in drug discovery and development due to patent expiry. Only a fraction of the disappearing revenues will return to the market due to currently available therapies, stringent payer demands and increased governmental influence on reimbursement. Due to these realities, Pharma are undergoing consolidation and the relationships between sponsor and CRO are changing — moving away from the traditional transactional approach toward structured, long-term strategic partnerships.
next IND has emerged as an innovative solution offering sponsors the expertise and customer intimacy found within niche CROs; while providing the capabilities of larger, full-service CROs.
next IND is an integrated service network comprised of six niche, expert CROs, each filling a key step in the drug development process. next IND provides clients a streamlined, tailor-made approach to drug development using a dedicated Program Manager as a single point of contact throughout every phase of the drug development pathway.
next IND´s steering committee, led by senior-level leadership from each partner company, designs a custom road map for a compound´s development. The compound follows its development path, seamlessly moving from one expert CRO to another, eliminating inefficiencies and unnecessary studies.
The seamless, ℠expert to expert´ approach decreases R&D costs and time-to-market while providing a high level of convenience and overall value. next IND is comprised of the following highly regarded CROs. In the non-clinical space, Cedarburg Hauser offers substance process development and manufacturing services,XenoTech offers in vitro drug metabolism services, Formurex offers preformulation and formulation services as well as GMP manufacturing, Xenometrics offers toxicology services and KCAS offers bioanalytical services. Clinical research services are provided by Vince & Associates Clinical Research.
For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2012/10/prweb10042153.htm